

November 10, 2020
Symbio Pharmaceuticals Limited
(Securities Code: 4582)
Fuminori Yoshida
Representative Director
President and Chief Executive Officer

Notice Concerning Non-operating Expenses

Symbio Pharmaceuticals Limited (“the Company”) announces accrued non-operating expenses for the third quarter of the fiscal year ending December 31, 2020 (from July 1, 2020 to September 30, 2020).

1. Details of Non-operating Expenses

The Company recorded a foreign exchange loss of 36,663 thousand yen under non-operating expenses for the third quarter of the fiscal year ending December 31, 2020 (from July 1, 2020 to September 30, 2020) due to recent fluctuations in foreign exchange rates. In addition, with a foreign exchange loss of 18,985 thousand yen for the first half ended June 30, 2020, a total foreign exchange loss of 55,648 thousand yen was recorded as statements of operations for the third quarter (cumulative) of the fiscal year ending December 31, 2020.

2. Future Outlook

The impact the above non-operating expenses on the results of Company operations is reflected on “Revision to Earnings Forecasts for FY2020 and Mid-Rage Plan (FY 2020 to FY 2022)” announced on September 17, 2020.

[Contact]

Investor Relations
Tel: +81(0)3 5472 1125